BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
read more...
Feb 24, 2023
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
read more...
Feb 03, 2023
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
read more...
Feb 01, 2023
BeiGene to Present at Upcoming Investor Conferences
read more...
Jan 19, 2023
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
read more...
Jan 19, 2023
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
read more...
Jan 18, 2023
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
read more...
Jan 17, 2023
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
read more...
Jan 04, 2023
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
read more...
Dec 30, 2022
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
read more...
Dec 13, 2022
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
read more...
Dec 09, 2022
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
read more...
Nov 22, 2022
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
read more...
Nov 17, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
read more...
Nov 15, 2022
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
read more...
Nov 10, 2022
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
read more...
Nov 09, 2022
BeiGene Reports Third Quarter 2022 Financial Results
read more...
Nov 04, 2022
BeiGene to Present at Upcoming Investor Conferences
read more...
Nov 03, 2022
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
read more...
Nov 02, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
read more...
